touchIN CONVERSATION

Selecting the optimal treatment for patients with chronic myeloid leukaemia after two prior lines of therapy

Access to this content is not permitted for healthcare professionals based in the US and UK.

Back to Education

This content is for healthcare professionals only.

This activity is funded by an independent medical education grant from Novartis.

This activity is provided by touchIME.

This content is intended for non-UK, non-US and non-Japan healthcare professionals.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues

    Downloads
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Simona Soverini

    University of Bologna, Bologna, Italy

    Prof. Simona Soverini is an associate professor of hematology at the Department of Experimental, Diagnostic and Speciality Medicine of the University of Bologna, and head of the Myeloid Leukemia Research group at the Institute of Hematology “Lorenzo e Ariosto Seragnoli” at the S. Orsola University Hospital in Bologna, Italy. read more

    She obtained her MSc in molecular biology and her PhD in clinical and experimental haematology from the University of Bologna. Her research focuses on chronic myeloid leukaemia and systemic mastocytosis. Prof. Soverini is author of over 170 publications in peer-reviewed journals, with a h-index of 50. She is a reviewer for a number of international journals, including Blood, Leukaemia, Haematologica, Clinical Cancer Research and the British Journal of Haematology, and sits in the editorial boards of the Journal of Hematology & Oncology, Frontiers in Oncology and the International Journal of Molecular Sciences. She is a member of the board of directors of the Italian Society of Experimental Hematology (SIES) and a member of the European Hematology Association (EHA), the American Society of Hematology (ASH) and the Society of Hematological Oncology (SOHO). She has served on the scientific program committees for EHA and SOHO congresses.

    Prof. Simona Soverini discloses: Advisory board fees from Cepheid and Blueprint Medicines. Consultancy fees from Incyte Biosciences.
    Dr Daniela Žáčková

    University Hospital Brno and Masaryk University, Brno, Czech Republic

    Daniela Žáčková, MD, PhD is consultant in haematology and associate professor at the Department of Internal Medicine Hematology and Oncology, University Hospital Brno, and Masaryk University, Brno, Czech Republic. read more

    Her scientific interest is mainly focused on the clinical and biological aspects of chronic myeloid leukemia (CML). She acts as a principal investigator of the nationwide, investigator-initiated, TKI-discontinuation, phase II trial HALF; co-investigator and national coordinator of international projects and trials, such as TIGER (CMLV) study, EURO-SKI/AFTER-SKI, PONDEROSA, and Blast Crisis Registry; and expert guarantor and national coordinator of the Czech Registry of CML patients, called INFINITY. She is a member of the European Hematology Association (EHA), European LeukemiaNet (ELN) Working Package 4 (WP4), Czech Leukemia Study Group for Life (CELL). She is on the advisory board of the patient supportive organization ’Diagnóza leukemie’ and an elected chair of the audit committee of the Czech Hematology Association. She is an author or co-author of more than 70 peer-reviewed articles, four scholarly books and eight peer-reviewed textbooks or textbook chapters.

    Prof. Daniela Žáčková discloses: Advisory board and speakers bureau fees from Angelini and Novartis. Consultancy fees from Angelini and Novartis. Travel support from Angelini, Bristol Myers Squibb, Novartis and Pfizer.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    Now Playing:
    Up Next:
    Take CE/CME Test
    Start activity
     
    Current treatment options to optimize outcomes for patients with CML after two lines of therapy
    New and emerging therapies for the treatment of patients with CML after two prior lines of therapy
    Impact of new and emerging treatments on the management of CML after two prior lines of therapy
    Take CE/CME Test

    touchIN CONVERSATION
    A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation. Close

    Selecting the optimal treatment for patients with chronic myeloid leukaemia after two prior lines of therapy

    Useful tips
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Discuss the treatment for patients with CML after two prior lines of therapy in clinical practice
    • Recall the latest clinical trial data for new and emerging treatments for patients with CML
    • Evaluate the possible impact of new and emerging treatments on the management of patients with CML after two prior lines of therapy
    Overview

    In this activity, two chronic myeloid leukaemia (CML) experts, Prof. Simona Soverini and Dr Daniela Žáčková, discuss the selection of optimal treatment for patients with CML after two prior lines of therapy. They consider the mechanisms of action and the latest clinical efficacy data of current and emerging therapies, and how these may impact the management of CML after two prior lines of therapy. The discussion is guided by pre-canvassed questions provided by the haematology oncology clinical community.

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchEXPERT OPINIONS

    The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial

    GO TO HUB

    touchMDT

    Multidisciplinary management of chronic myeloid leukaemia in the later-line setting: A holistic approach

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Alessandra Tedeschi, EHA 2019 – Ibrutinib for First-line Treatment of CLL

    GO TO HUB

    JOURNALS

    Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma

    GO TO ARTICLE

    JOURNALS

    Capturing Alloreactivity in Multiple Myeloma

    GO TO ARTICLE

    Topics covered in this activity

    Haematological Malignancies / Haematology / Leukaemia
    Register to touchONCOLOGY for FREE
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 8 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from Novartis. This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 3 November 2022.

    Claim Credit
    touchIN CONVERSATION
    Selecting the optimal treatment for patients with chronic myeloid leukaemia after two prior lines of therapy

    You may also be interested in...

    touchPANEL DISCUSSION

    Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchCONGRESS

    Current and emerging treatments for chronic myeloid leukemia: What have we learnt from EHA Hybrid Conference 2022?

    LAUNCH ACTIVITY
    Arnon P Kater_T.JPG

    CONFERENCE HUB

    Arnon P Kater, EHA 2018 – TP53 Mutations in Relapsed/Refractory CLL – the MURANO Trial

    GO TO HUB
    Annalisa Chiappella_T.JPG

    CONFERENCE HUB

    Annalisa Chiappella, EHA 2018 – TP53 Mutations in DLBCL: the FIL-DLCL04 Study

    GO TO HUB

    JOURNALS

    Platelets – From Function to Dysfunction in Essential Thrombocythaemia

    GO TO ARTICLE

    JOURNALS

    Haemophilia Treatment – Current and Future Challenges

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from Novartis. This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 3 November 2022.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72